Clinical validation of circulating cell free DNA [ccfDNA] as a biomarker of metabolic health

Not Applicable

• Conditions: Metabolic Health; Obesity; Metabolic and Endocrine - Metabolic disorders; Diet and Nutrition - Obesity

• Registration Number: ACTRN12622001326785
• Lead Sponsor: Commonwealth Scientific and Industrial Research Organisation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-12
• Last Update Posted: 16 October 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1.Willing to provide written Informed Consent
2.Aged from >=18 to <56 years of age at clinic visit
3.BMI >=30 and <=35 kg/m2 confirmed at visit
4.Willing to fast at least 10 hours before attending clinic visit

Exclusion Criteria

1.Currently pregnant and/or nursing (lactating)
2.Diagnosis of insulin resistance, diabetes (Type I, Type II and/or Gestational Diabetes), cancer including skin cancer, and immunological disease
3.Current or prior chemotherapy/radiotherapy treatment
4.Current use or use of the following medications in the last 84 days prior to clinic visit:
•Metformin
•Fortamet
•Glucophage
•Glucophage XR
•Glumetza
•Riomet
•N,N-dimethylbiguanide
5.Experienced physical injury 14 days prior to clinic visit that meets any of the following:
•Required medical assessment and/or treatment
•Resulted in pain, bruising and/or sensitivity lasting longer than 14 days or is currently being experienced.
•Resulted in limited movement and mobility
6.Average Systolic BP >=180mmHg or Diastolic BP >= 110mmHg
7.In the opinion of the Principal Investigator, unable to comply and/or experience distress with study procedures.

Study & Design

• Study Type: Observational
• Study Design: Not specified